Table I.
Enriched gene sets for three comparisons: BPA vs. Control, C+OF vs. Control, and BPA+OF vs. C+OF. The first 20 gene sets are the top most significant in at least one comparison. The remaining 15 gene sets are related to the cardiovascular system and significant in at least one comparison. Numbers in parentheses for Gene Set Type represent the number of analyzed genes in the gene set; numbers in parentheses for Direction are the number of significant genes in that category for the corresponding comparison.
| No | Gene Set ID | Gene Set Name | Gene Set Type (Size) | BPA vs. Control | C+OF vs. Control | BPA+OF vs. C+OF | |||
|---|---|---|---|---|---|---|---|---|---|
| Direction (# genes) | q-value | Direction (# genes) | q-value | Direction (#genes) | q-value | ||||
| 1 | GO:0016491 | oxidoreductase activity | GOMF (724) | down (53) | 9.96E-12 | down (102) | 2.05E-13 | up (40) | 2.78E-05 |
| 2 | GO:0045047 | protein targeting to ER | GOBP (84) | down (16) | 3.10E-11 | down (40) | 7.92E-21 | down (3) | 8.01E-02 |
| 3 | GO:0055114 | oxidation-reduction process | GOBP (935) | down (78) | 4.79E-11 | down (127) | 1.24E-12 | up (57) | 1.09E-05 |
| 4 | GO:0006414 | translational elongation | GOBP (87) | down (19) | 2.09E-08 | down (43) | 1.71E-17 | down (3) | 2.93E-01 |
| 5 | GO:0051276 | chromosome organization | GOBP (952) | up (26) | 2.31E-06 | up (53) | 2.97E-08 | down (11) | 1.08E-01 |
| 6 | GO:0016570 | histone modification | GOBP (393) | up (15) | 1.33E-03 | up (34) | 2.82E-05 | down (4) | 3.79E-01 |
| 7 | GO:0006936 | muscle contraction | GOBP (283) | down (25) | 2.80E-01 | down (40) | 5.77E-01 | up (20) | 7.86E-04 |
| 8 | GO:0006954 | inflammatory response | GOBP (452) | down (34) | 1.51E-09 | down (39) | 8.59E-06 | up (22) | 1.24E-02 |
| 9 | GO:0038066 | p38MAPK cascade | GOBP (12) | down (1) | 8.28E-01 | down (3) | 4.71E-01 | up (3) | 1.10E-03 |
| 10 | GO:0046330 | positive regulation of JNK cascade | GOBP (52) | down (6) | 9.92E-01 | down (7) | 3.51E-01 | up (8) | 1.03E-03 |
| 11 | GO:0003735 | structural constituent of ribosome | GOMF (111) | down (22) | 3.77E-18 | down (53) | 2.85E-28 | down (3) | 9.90E-01 |
| 12 | GO:0006614 | SRP-dependent cotranslational protein targeting to membrane | GOBP (77) | down (16) | 2.93E-11 | down (40) | 7.92E-21 | down (3) | 7.16E-02 |
| 13 | GO:0005615 | extracellular space | GOCC (722) | down (88) | 1.89E-13 | down (108) | 7.88E-16 | up (65) | 4.29E-02 |
| 14 | GO:0005743 | mitochondrial inner membrane | GOCC (417) | down (26) | 2.34E-10 | down (59) | 3.42E-11 | up (11) | 3.56E-03 |
| 15 | GO:0044429 | mitochondrial part | GOCC (938) | down (45) | 1.52E-09 | down (98) | 1.42E-10 | up (32) | 2.99E-04 |
| 16 | GO:0022904 | respiratory electron transport chain | GOBP (127) | down (12) | 5.50E-09 | down (28) | 8.45E-11 | up (4) | 2.21E-01 |
| 17 | GO:0002685 | regulation of leukocyte migration | GOBP (95) | down (8) | 4.44E-02 | down (13) | 1.10E-02 | up (10) | 1.54E-03 |
| 18 | GO:0001071 | nucleic acid binding transcription factor activity | GOMF (883) | up (39) | 8.77E-05 | up (69) | 4.84E-13 | down (21) | 7.94E-02 |
| 19 | GO:0042044 | fluid transport | GOBP (31) | up (5) | 7.44E-02 | up (3) | 1.22E-01 | down (3) | 2.39E-03 |
| 20 | 882901 | 5-Hydroxytryptamine degradation | Panther (14) | down (1) | 3.79E-01 | down (3) | 3.04E-01 | up (4) | 2.65E-06 |
| 21 | GO:0055024 | regulation of cardiac muscle tissue development | GOBP (41) | up (3) | 9.58E-03 | up (6) | 1.03E-02 | down (1) | 9.95E-01 |
| 22 | GO:0055015 | ventricular cardiac muscle cell development | GOBP (11) | up (1) | 2.75E-02 | up (3) | 3.50E-01 | down (1) | 9.40E-01 |
| 23 | GO:0021591 | ventricular system development | GOBP (21) | up (1) | 4.74E-02 | up (2) | 4.19E-02 | down (1) | 3.71E-01 |
| 24 | GO:0033275 | actin-myosin filament sliding | GOBP (40) | down (5) | 5.11E-05 | down (4) | 9.37E-05 | up (1) | 2.53E-01 |
| 25 | hsa04310 | Wnt signaling pathway | KEGG (119) | up (4) | 6.63E-03 | up (12) | 8.84E-03 | down (6) | 3.49E-01 |
| 26 | 882841 | Endothelin signaling pathway | Panther (64) | up (5) | 1.70E-02 | up (8) | 3.90E-01 | down (2) | 4.66E-01 |
| 27 | GO:0061061 | muscle structure development | GOBP (525) | up (30) | 5.06E-01 | up (60) | 2.17E-02 | down (19) | 9.83E-01 |
| 28 | 882953 | Apoptosis signaling pathway | Panther (95) | up (5) | 8.64E-01 | up (12) | 1.82E-02 | down (7) | 2.13E-01 |
| 29 | GO:0007173 | epidermal growth factor receptor signaling pathway | GOBP (202) | up (13) | 2.91E-02 | up (30) | 8.32E-06 | down (9) | 1.63E-01 |
| 30 | GO:0005104 | fibroblast growth factor receptor binding | GOMF (11) | up (1) | 2.00E-03 | up (3) | 1.92E-04 | down (1) | 1.81E-02 |
| 31 | 884942 | FOXO1_02 | TFs (225) | up (13) | 5.15E-04 | up (28) | 2.40E-04 | down (7) | 1.84E-01 |
| 32 | 885009 | FOXO3_01 | TFs (174) | up (11) | 1.55E-02 | up (16) | 9.45E-03 | down (4) | 1.01E-01 |
| 33 | 884988 | GATA1_05 | TFs (151) | up (13) | 1.55E-02 | up (22) | 2.98E-03 | down (9) | 8.25E-01 |
| 34 | hsa04010 | MAPK signaling pathway | KEGG (220) | up (12) | 1.17E-02 | up (34) | 5.43E-04 | down (18) | 9.96E-01 |
| 35 | GO:0071356 | cellular response to tumor necrosis factor | GOBP (82) | down (6) | 1.94E-01 | down (14) | 5.80E-02 | up (9) | 1.54E-03 |